Skip to content
Ceftibuten
Cedax (ceftibuten) is a small molecule pharmaceutical. Ceftibuten was first approved as Cedax on 1995-12-20. It is used to treat bacterial infections, bronchitis, escherichia coli infections, haemophilus infections, and klebsiella infections amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
stomatognathic diseasesD009057
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ceftibuten dihydrate
Tradename
Company
Number
Date
Products
CEDAXSI PharmaceuticalsN-050685 DISCN1995-12-20
1 products
CEDAXSI PharmaceuticalsN-050686 DISCN1995-12-20
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cedaxNew Drug Application2010-01-12
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial infections—D001424A49
bronchitis—D001991J40
escherichia coli infectionsEFO_1001318D004927B96.20
haemophilus infectionsEFO_1001127D006192—
klebsiella infectionsEFO_1001353D007710—
moraxellaceae infectionsEFO_1001072D045828—
otitis mediaEFO_0004992D010033H66.9
streptococcal infectionsEFO_1001476D013290—
tonsillitisHP_0011110D014069J03
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DD: Third-generation cephalosporins
— J01DD14: Ceftibuten
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCEFTIBUTEN
INNceftibuten
Description
Ceftibuten is a third-generation cephalosporin antibiotic with a [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino substituent at the 7 position of the cephem skeleton. An orally-administered agent, ceftibuten is used as the dihydrate to treat urinary-tract and respiratory-tract infections. It has a role as an antibacterial drug. It is a cephalosporin and a dicarboxylic acid.
Classification
Small molecule
Drug classcephalosporins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1nc(/C(=C/CC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@H]23)cs1
Identifiers
PDB—
CAS-ID97519-39-6
RxCUI20492
ChEMBL IDCHEMBL1605
ChEBI ID3510
PubChem CID5282242
DrugBankDB01415
UNII IDIW71N46B4Y (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 576 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
9 adverse events reported
View more details